Related Experiment Video
Updated: Mar 11, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
[Effect and Significance of BIM on Non-small Cell Lung Cancer]
1Department of Medical Oncology, the 2nd Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Abstract:
B-cell lymphoma 2 interacting mediator of cell death (BIM) plays an important role in the progress of cell apoptosis. The lowering expression level or functional defect of which may have an negative effect on the efficacy of anticancer drugs and the prognosis of postoperative patients with non-small cell lung cancer (NSCLC). This review aims to summarize the structure and function of BIM, as well as the relationship between BIM and the therapeutic efficacy of NSCLC.
Insights
B-cell lymphoma 2 interacting mediator of cell death (BIM) is crucial for apoptosis. Lower BIM levels may reduce anticancer drug effectiveness and worsen outcomes for non-small cell lung cancer (NSCLC) patients.
Area of Science:
- Molecular Biology
- Oncology
- Cell Death Research
Background:
- B-cell lymphoma 2 interacting mediator of cell death (BIM) is a key regulator of apoptosis.
- Dysregulation of BIM is implicated in various diseases, including cancer.
- Understanding BIM's role is vital for developing effective cancer therapies.
Purpose of the Study:
- To review the structure and function of BIM.
- To explore the relationship between BIM and non-small cell lung cancer (NSCLC) progression.
- To analyze BIM's impact on the efficacy of anticancer treatments for NSCLC.
Main Methods:
- Literature review of scientific articles on BIM and NSCLC.
- Analysis of BIM's molecular mechanisms in apoptosis.
- Correlation of BIM expression levels with therapeutic outcomes in NSCLC patients.
Main Results:
- BIM's structure and function in regulating apoptosis are detailed.
- Evidence suggests reduced BIM expression or defects negatively impact NSCLC patient prognosis.
- Lower BIM levels may compromise the effectiveness of current NSCLC therapies.
Conclusions:
- BIM is a critical factor in NSCLC pathogenesis and treatment response.
- Maintaining BIM integrity and expression is important for improving therapeutic efficacy.
- Targeting BIM could represent a promising strategy for NSCLC treatment.
